Atea Pharmaceuticals (AVIR) Hisse Özeti
Klinik aşamada bir biyofarmasötik şirketi olan Atea Pharmaceuticals, Inc. ciddi viral enfeksiyonları olan hastalar için oral antiviral terapötikler keşfetmekte, geliştirmekte ve ticarileştirmektedir. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 2/6 |
| Gelecekteki Büyüme | 2/6 |
| Geçmiş Performans | 0/6 |
| Finansal Sağlık | 6/6 |
| Temettüler | 0/6 |
AVIR Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Atea Pharmaceuticals, Inc. Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$4.91 |
| 52 Haftanın En Yüksek Seviyesi | US$6.45 |
| 52 Haftanın En Düşük Seviyesi | US$2.78 |
| Beta | 0.32 |
| 1 Aylık Değişim | 12.61% |
| 3 Aylık Değişim | -13.40% |
| 1 Yıllık Değişim | 29.89% |
| 3 Yıllık Değişim | 30.93% |
| 5 Yıllık Değişim | -77.69% |
| Halka arzdan bu yana değişim | -83.82% |
Son Haberler & Güncellemeler
Anlatı Güncellemesi • Jun 26
AVIR: Hepatitis Antiviral Pipeline Progress Will Drive A More Optimistic Outlook
The analyst price target for Atea Pharmaceuticals has moved by about $1.00, with analysts pointing to revised fair value, discount rate, revenue growth, profit margin, and future P/E assumptions as the main drivers of this update. What's in the News Atea Pharmaceuticals reported Phase 1 results indicating its fixed-dose combination of bemnifosbuvir and ruzasvir for hepatitis C had a low risk of drug drug interactions, including with commonly used medications such as omeprazole and rosuvastatin.Seeking Alpha • May 29
Atea Pharmaceuticals: I'm Optimistic Ahead Of Critical HPV Catalyst
Summary Atea Pharmaceuticals, Inc. receives a buy rating ahead of pivotal phase 3 BEM/RZR hepatitis C data expected mid-2026. AVIR’s BEM/RZR targets a differentiated, short-duration, pan-genotypic HCV regimen, aiming for >95% sustained virologic response and low drug-drug interactions. AVIR’s $256m cash runway extends through 2027, but commercial viability hinges on phase 3 success versus entrenched competitors Gilead and AbbVie. Failure in both Phase 3 studies threatens AVIR’s survival, while success could trigger a share price spike or potential acquisition interest. Read the full article on Seeking Alpha
Yeni Anlatı • May 15
Hepatitis C Trial And Pricing Risks Will Dominate Outlook Yet Longer Term Potential Remains
Catalysts About Atea Pharmaceuticals Atea Pharmaceuticals focuses on developing oral antiviral therapies for hepatitis C and hepatitis E. What are the underlying business or industry changes driving this perspective?Analiz Makalesi • May 14
We Think Atea Pharmaceuticals (NASDAQ:AVIR) Needs To Drive Business Growth Carefully
We can readily understand why investors are attracted to unprofitable companies. For example, although...Recent updates
Anlatı Güncellemesi • Jun 26
AVIR: Hepatitis Antiviral Pipeline Progress Will Drive A More Optimistic Outlook
The analyst price target for Atea Pharmaceuticals has moved by about $1.00, with analysts pointing to revised fair value, discount rate, revenue growth, profit margin, and future P/E assumptions as the main drivers of this update. What's in the News Atea Pharmaceuticals reported Phase 1 results indicating its fixed-dose combination of bemnifosbuvir and ruzasvir for hepatitis C had a low risk of drug drug interactions, including with commonly used medications such as omeprazole and rosuvastatin.Seeking Alpha • May 29
Atea Pharmaceuticals: I'm Optimistic Ahead Of Critical HPV Catalyst
Summary Atea Pharmaceuticals, Inc. receives a buy rating ahead of pivotal phase 3 BEM/RZR hepatitis C data expected mid-2026. AVIR’s BEM/RZR targets a differentiated, short-duration, pan-genotypic HCV regimen, aiming for >95% sustained virologic response and low drug-drug interactions. AVIR’s $256m cash runway extends through 2027, but commercial viability hinges on phase 3 success versus entrenched competitors Gilead and AbbVie. Failure in both Phase 3 studies threatens AVIR’s survival, while success could trigger a share price spike or potential acquisition interest. Read the full article on Seeking AlphaYeni Anlatı • May 15
Hepatitis C Trial And Pricing Risks Will Dominate Outlook Yet Longer Term Potential Remains
Catalysts About Atea Pharmaceuticals Atea Pharmaceuticals focuses on developing oral antiviral therapies for hepatitis C and hepatitis E. What are the underlying business or industry changes driving this perspective?Analiz Makalesi • May 14
We Think Atea Pharmaceuticals (NASDAQ:AVIR) Needs To Drive Business Growth Carefully
We can readily understand why investors are attracted to unprofitable companies. For example, although...
Yeni Anlatı • Mar 19
Hepatitis Antiviral Pipeline Will Create Long Term Upside Potential
Catalysts About Atea Pharmaceuticals Atea Pharmaceuticals focuses on developing oral direct acting antiviral therapies for serious viral infections, including hepatitis C and hepatitis E. What are the underlying business or industry changes driving this perspective?Yeni Anlatı • Mar 05
Hepatitis C And E Antiviral Pipeline Will Reshape Long Term Outlook
Catalysts About Atea Pharmaceuticals Atea Pharmaceuticals is a clinical stage biotechnology company focused on developing oral direct acting antivirals for serious viral infections, including hepatitis C and hepatitis E. What are the underlying business or industry changes driving this perspective?Seeking Alpha • Sep 26
Atea wins FDA Fast Track status for dengue treatment
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR), a biotech focused on developing treatments for viral infections, announced Monday that the FDA granted Fast Track Designation to AT-752, an investigational oral therapy for dengue virus infection. Dengue is the most common mosquito-borne virus in the world, affecting an estimated up to 400M people annually. The FDA offers the Fast Track designation to accelerate the development and review of drugs targeted at serious conditions with unmet medical needs. It allows developers to communicate frequently with the regulator on plans for clinical studies. Developed using AVIR’s purine nucleotide prodrug platform, AT-752 is currently undergoing two proof-of-concept studies for dengue, with data expected at the end of the year. Read more on upcoming milestones for AVIR as outlined by the management in August.Seeking Alpha • Aug 08
Atea Pharmaceuticals Q2 2022 Earnings Preview
Atea Pharmaceuticals (NASDAQ:AVIR) is scheduled to announce Q2 earnings results on Monday, August 8th, after market close. The consensus EPS Estimate is -$0.49 (-2550.0% Y/Y) and the consensus Revenue Estimate is $0M Over the last 3 months, EPS estimates have seen 2 upward revisions and 1 downward.Analiz Makalesi • May 13
Atea Pharmaceuticals, Inc.'s (NASDAQ:AVIR) Shares Not Telling The Full Story
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") above 16x, you may...Analiz Makalesi • Jan 05
Analysts Just Shaved Their Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Forecasts Dramatically
Today is shaping up negative for Atea Pharmaceuticals, Inc. ( NASDAQ:AVIR ) shareholders, with the analysts delivering...Analiz Makalesi • Nov 25
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Analysts Just Slashed Next Year's Estimates
The latest analyst coverage could presage a bad day for Atea Pharmaceuticals, Inc. ( NASDAQ:AVIR ), with the analysts...Analiz Makalesi • Oct 24
A Look Into The Ownership Structure of Atea Pharmaceuticals (NASDAQ:AVIR)
Now and then, the volatility of the pharmaceutical sector rears its ugly head, leaving the hordes of investors running for the hills. Leading the decline this week was Atea Pharmaceuticals (NasdaqGS: AVIR) that lost over two-thirds of its value. We will look into this severe decline and reflect on the state of the ownership.Analiz Makalesi • Oct 24
A Look Into The Ownership Structure of Atea Pharmaceuticals (NASDAQ:AVIR)
Now and then, the volatility of the pharmaceutical sector rears its ugly head, leaving the hordes of investors running for the hills. Leading the decline this week was Atea Pharmaceuticals (NasdaqGS: AVIR) that lost over two-thirds of its value. We will look into this severe decline and reflect on the state of the ownership.Seeking Alpha • Oct 20
Atea Pharmaceuticals' COVID Antiviral Trial Failure Hands Initiative To Merck's Molnupiravir
Atea Pharmaceuticals posted underwhelming data from a Phase 2 trial of its COVID antiviral therapy AT-527 on Oct. 19, causing its stock price to fall by 66%. The drug failed to meet its endpoint of reduction of the SARS-Cov-2 virus compared to placebo in a subset of patients - around two-thirds of whom were low risk. Atea has a similar mechanism of action to Merck's Molnupiravir, which looks likely to win Emergency Approval for mild-to-moderate COVID-19 patients who are at risk for progressing to severe COVID. If Atea management has used only unvaccinated patients with a serious underlying health issue, as Merck did, the outcome of its MOONSONG trial may have been different. As such, Atea may be able to alter pivotal trial protocols and still make it to market - although yesterday's data means that will not happen for at least another year, by which time, it may be too late.Hissedar Getirileri
| AVIR | US Pharmaceuticals | US Pazar | |
|---|---|---|---|
| 7D | -1.4% | -0.5% | 0.6% |
| 1Y | 29.9% | 45.8% | 19.5% |
Getiri vs. Endüstri: AVIR geçen yıl % 45.8 oranında getiri sağlayan US Pharmaceuticals sektörünün gerisinde kaldı.
Getiri vs Piyasa: AVIR geçen yıl % 19.5 oranında getiri sağlayan US Piyasasını aştı.
Fiyat Oynaklığı
| AVIR volatility | |
|---|---|
| AVIR Average Weekly Movement | 7.4% |
| Pharmaceuticals Industry Average Movement | 9.2% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
İstikrarlı Hisse Senedi Fiyatı: AVIR son 3 ayda US piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: AVIR 'nin haftalık oynaklığı ( 7% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 2012 | 55 | Jean-Pierre Sommadossi | ateapharma.com |
Klinik aşamada bir biyofarmasötik şirketi olan Atea Pharmaceuticals, Inc. ciddi viral enfeksiyonları olan hastalar için oral antiviral terapötikler keşfetmekte, geliştirmekte ve ticarileştirmektedir. Şirketin öncü ürün adayı, hepatit C virüsü (HCV) tedavisi için Faz 3 klinik çalışmasında olan bir nükleotid NS5B inhibitörü olan bemnifosbuvir ve bir NS5A inhibitörü olan ruzasvir rejimidir. Şirket ayrıca kronik HEV enfeksiyonunun tedavisi için Faz 1 klinik çalışmasında olan AT-587'yi geliştirmektedir.
Atea Pharmaceuticals, Inc. Temel Bilgiler Özeti
| AVIR temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$384.93m |
| Kazançlar(TTM) | -US$169.52m |
| Gelir(TTM) | n/a |
0.0x
P/S Oranı-2.3x
F/K OranıAVIR aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| AVIR gelir tablosu (TTM) | |
|---|---|
| Gelir | US$0 |
| Gelir Maliyeti | US$159.32m |
| Brüt Kâr | -US$159.32m |
| Diğer Giderler | US$10.20m |
| Kazançlar | -US$169.52m |
Son Raporlanan Kazançlar
Mar 31, 2026
Sonraki Kazanç Tarihi
n/a
| Hisse başına kazanç (EPS) | -2.12 |
| Brüt Marj | 0.00% |
| Net Kâr Marjı | 0.00% |
| Borç/Özkaynak Oranı | 0% |
AVIR uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/07/09 15:14 |
| Gün Sonu Hisse Fiyatı | 2026/07/09 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları GitHub sayfamızda mevcuttur; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Atea Pharmaceuticals, Inc. 4 Bu analistlerden 2, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Eric Joseph | J.P. Morgan |
| Matthew Harrison | Morgan Stanley |
| Maxwell Skor | Morgan Stanley |